CIDeRplusGeneral Information:
| Id: | 3,654 |
| Diseases: |
Diabetes mellitus, type II
- [OMIM]
Insulin resistance |
| Mammalia | |
| article/cited | |
| Reference: | Wang-Sattler R et al.(2012) Novel biomarkers for pre-diabetes identified by metabolomics Mol. Syst. Biol. 8: 615 [PMID: 23010998] |
Interaction Information:
| Comment | Insulin represses ALAS-H expression. (cited information) |
|
Formal Description Interaction-ID: 34725 |
|
| Drugbank entries | Show/Hide entries for ALAS1 |
| Comment | ALAS-H catalyzes the condensation of glycine and succinyl-CoA into 5-aminolevulinic acid. (cited information) |
|
Formal Description Interaction-ID: 34727 |
|
| Drugbank entries | Show/Hide entries for ALAS1 or Glycine |
| Comment | ALAS-H catalyzes the condensation of glycine and succinyl-CoA into 5-aminolevulinic acid. (cited information) |
|
Formal Description Interaction-ID: 34728 |
|
| Drugbank entries | Show/Hide entries for ALAS1 |
| Comment | ALAS-H catalyzes the condensation of glycine and succinyl-CoA into 5-aminolevulinic acid. (cited information) |
|
Formal Description Interaction-ID: 34729 |
|
| Drugbank entries | Show/Hide entries for ALAS1 |
| Comment | Acetylcarnitine is produced by the mitochondrial matrix enzyme, CrAT, from carnitine and acetyl-CoA, a molecule that is a product of both fatty acid beta-oxidation and glucose oxidation and can be used by the citric acid cycle for energy generation. (cited information) |
|
Formal Description Interaction-ID: 34731 |
gene/protein increases_quantity of drug/chemical compound |
| Drugbank entries | Show/Hide entries for CRAT |
| Comment | Acetylcarnitine is produced by the mitochondrial matrix enzyme, CrAT, from carnitine and acetyl-CoA, a molecule that is a product of both fatty acid beta-oxidation and glucose oxidation and can be used by the citric acid cycle for energy generation. (cited information) |
|
Formal Description Interaction-ID: 34732 |
|
| Drugbank entries | Show/Hide entries for CRAT |
| Comment | Acetylcarnitine is produced by the mitochondrial matrix enzyme, CrAT, from carnitine and acetyl-CoA, a molecule that is a product of both fatty acid beta-oxidation and glucose oxidation and can be used by the citric acid cycle for energy generation. (cited information) |
|
Formal Description Interaction-ID: 34733 |
gene/protein decreases_quantity of drug/chemical compound |
| Drugbank entries | Show/Hide entries for CRAT |
| Comment | Individuals with IGT and dT2D had lower cPLA2 transcription levels, suggesting reduced cPLA2 activity. As a result, a concomitant decrease in the concentration of arachidonic acid (AA), a product of cPLA2 activity, is expected. AA has been shown to inhibit glucose uptake by adipocytes in a mechanism that is probably insulin independent and that involves the GLUT-1 transporter. (cited information) |
|
Formal Description Interaction-ID: 34734 |
|
| Drugbank entries | Show/Hide entries for PLA2G4A or Arachidonic acid |
| Comment | Individuals with IGT and dT2D had lower cPLA2 transcription levels, suggesting reduced cPLA2 activity. As a result, a concomitant decrease in the concentration of arachidonic acid (AA), a product of cPLA2 activity, is expected. AA has been shown to inhibit glucose uptake by adipocytes in a mechanism that is probably insulin independent and that involves the GLUT-1 transporter. (cited information) |
|
Formal Description Interaction-ID: 34736 |
drug/chemical compound decreases_activity of process |
| Drugbank entries | Show/Hide entries for Arachidonic acid |